Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA

被引:8
作者
Shah, Kavit [1 ]
Clark, Alexander [2 ]
Desai, Shashvat M. [3 ]
Jadhav, Ashutosh P. [3 ]
机构
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Barrow Neurol Inst, Phoenix, AZ 85013 USA
关键词
Stroke; Thrombolytic therapy; Intracranial hemorrhage; Ischemia; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; INTRAVENOUS THROMBOLYSIS; SCIENTIFIC STATEMENT; EARLY MANAGEMENT; RISK; TRANSFORMATION; IMPROVEMENT; GUIDELINES;
D O I
10.1007/s12028-021-01266-5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background Acute ischemic stroke (AIS) is a major contributor toward healthcare-associated costs and services. Symptomatic intracranial hemorrhage (sICH) and early neurologic decline (END), defined as a National Health Institute Stroke Scale score decline of >= 4 within 24 h (with or without sICH), remain major concerns when administering intravenous tissue plasminogen activator (IV tPA) despite improved functional neurologic outcomes with its use. Given these risks, current guidelines recommend comprehensive stroke care (most often in an intensive care unit setting) for 24 h posttreatment. However, a number of patients may remain stable after IV tPA and thus not require such intensive resources. We sought to determine causes of END, along with timing and predictors of both sICH and END, to identify patients at lower risk of neurological deterioration and those suitable for earlier transition to a lower level of care. Methods This present study analyzed patients with AIS that presented within 4.5 h of being last seen well and received IV tPA. Baseline demographic, clinical, and radiographic findings were collected. Outcomes included END from any cause, parenchymal hemorrhage (PH1 or PH2), sICH, and mortality at 90 days. Results A total of 1238 patients with AIS without acute treatment of large vessel occlusion received IV tPA. 9.4% (116) had presence of any degree of ICH on noncontrast computed tomography head and 7.4% (91) experienced associated END. 2.7% (33) of patients experienced sICH, while 6.7% (83) experienced asymptomatic ICH. Of the patients with END, 63.7% did not have ICH. Predictive factors at presentation for END included an older age (72.6 +/- 16.1 vs. 69.1 +/- 14.8, p = 0.03), history of tobacco use (odds ratio [OR] 2.1 [1.1-4.3], p = 0.04), and hyperlipidemia (OR 1.7 [1.1-2.8], p = 0.02), along with the presence of an untreated large vessel occlusion (OR 2.1 [1.4-3.1], p = 0.02). Most END occurred within a mean time of 242 +/- 251 min (4 +/- 4 h). Because of the small proportion of patients suffering from sICH (33), predictors could not be determined; however, for patients with any ICH, predictive factors included an older age (74.6 +/- 12.4 vs. 68.8 +/- 15.1, p = 0.001), higher baseline National Health Institute Stroke Scale score (14.6 +/- 7.3 vs. 10.8 +/- 7.9, p = 0.002), and higher baseline glucose levels (155.1 +/- 87.5 vs. 140.4 +/- 70.5, p = 0.04). Conclusions In this study, only a small proportion suffered from either sICH and/or END, typically within 12 h of tPA administration. These findings may support earlier deescalation of higher acuity monitoring in clinically stable post-IV tPA patients without large vessel occlusion.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 22 条
[1]   Guidelines for the early management of patients with ischemic stroke - A scientific statement from the Stroke Council of the American Stroke Association [J].
Adams, HP ;
Adams, RJ ;
Brott, T ;
del Zoppo, GJ ;
Furlan, A ;
Goldstein, LB ;
Grubb, RL ;
Higashida, R ;
Kidwell, C ;
Kwiatkowski, TG ;
Marler, JR ;
Hademenos, GJ .
STROKE, 2003, 34 (04) :1056-1083
[2]  
Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI [10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000530]
[3]   Safety Trial of Low-Intensity Monitoring After Thrombolysis: Optimal Post Tpa-Iv Monitoring in Ischemic STroke (OPTIMIST) [J].
Faigle, Roland ;
Butler, Jaime ;
Carhuapoma, Juan R. ;
Johnson, Brenda ;
Zink, Elizabeth K. ;
Shakes, Tenise ;
Rosenblum, Melissa ;
Saheed, Mustapha ;
Urrutia, Victor C. .
NEUROHOSPITALIST, 2020, 10 (01) :11-15
[4]   Multicenter Study of Adverse Events After Intravenous Tissue-Type Plasminogen Activator Treatment of Acute Ischemic Stroke [J].
Fernandez-Gotico, Hannah ;
Lightfoot, Tiffany ;
Meighan, Melissa .
JOURNAL OF NEUROSCIENCE NURSING, 2017, 49 (01) :31-36
[5]   Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis [J].
Georgiadis, Dimitrios ;
Engelter, Stefan ;
Tettenborn, Barbara ;
Hungerbuehler, Hansjoerg ;
Luethy, Regina ;
Mueller, Felix ;
Arnold, Marcel ;
Giambarba, Christian ;
Baumann, Christian Rainer ;
von Buedingen, Hans-Christian ;
Lyrer, Philipp ;
Baumgartner, Ralf Werner .
CIRCULATION, 2006, 114 (03) :237-241
[6]   Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial [J].
Grotta, JC ;
Welch, KMA ;
Fagan, SC ;
Lu, M ;
Frankel, MR ;
Brott, T ;
Levine, SR ;
Lyden, PD .
STROKE, 2001, 32 (03) :661-668
[7]  
Group, 2017, STROKE, V28, P2118
[8]  
GROUP TNIONDASr-PSS, 2017, NEW ENGL J MED, V28, P2109
[9]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[10]   Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].
Hacke, Werner ;
Kaste, Markku ;
Bluhmki, Erich ;
Brozman, Miroslav ;
Davalos, Antoni ;
Guidetti, Donata ;
Larrue, Vincent ;
Lees, Kennedy R. ;
Medeghri, Zakaria ;
Machnig, Thomas ;
Schneider, Dietmar ;
von Kummer, Ruediger ;
Wahlgren, Nils ;
Toni, Danilo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329